The US Food and Drug Administration (USFDA) has completed a pre-approval inspection at Casper Pharma formulations manufacturing facility situated at GMR Hyderabad SEZ, a wholly owned subsidiary of Suven Pharmaceuticals Hyderabad, India.
The inspection was conducted from July 25 through Jul 29, 2022. The audit is part of the agency’s inspection for three product applications filed and slated to be manufactured at this site.
Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
